Health Care Technology

LifeMD

LifeMD released FY2026 Q1 earnings on May 6 After-Market EST, actual revenue USD 50.16 M (forecast USD 49.1 M), actual EPS USD -0.2038 (forecast USD -0.2333)

LifeMD to Release FY2026 Q1 Earnings on May 6 After-Market EST, Forecast Revenue USD 48.88 M, EPS USD -0.2333

LifeMD released FY2025 Annual Earnings on March 9 After-Market EST, actual revenue USD 194.06 M (forecast USD 228.78 M), actual EPS USD 0.2492 (forecast USD -0.2142)

LifeMD released FY2025 Q4 earnings on March 9 After-Market EST, actual revenue USD 46.87 M (forecast USD 45.61 M), actual EPS USD 0.4096 (forecast USD -0.0657)

LifeMD to Release FY2025 Q4 Earnings on March 9 After-Market EST, Forecast Revenue USD 48.57 M, EPS USD -0.06

LifeMD Expands Collaboration with Novo Nordisk to Offer Wegovy Pills

Mizuho Securities Downgrades LifeMD's Target Price to $6.00

LifeMD released FY2025 Q3 earnings on November 17 After-Market EST, actual revenue USD 60.17 M (forecast USD 62.13 M), actual EPS USD -0.1 (forecast USD -0.045)

LifeMD released FY2025 9 Months Earnings on November 17 After-Market EST, Actual Revenue: USD 172.17 M, Actual EPS: USD -0.2115

LifeMD Inc Submits Untimely 10-Q Report to SEC and Confirms Overstated Revenue

LifeMD Sells Majority Stake in WorkSimpli Software for $22 Million

LifeMD to Release FY2025 Q3 Earnings on November 6 After-Market EST, Forecast Revenue USD 62.13 M, EPS USD -0.045

LifeMD released FY2025 Q2 earnings on August 5 After-Market EST, actual revenue USD 61.1 M (forecast USD 66.31 M), actual EPS USD -0.0892 (forecast USD -0.0083)

LifeMD released FY2025 Semi-Annual earnings on August 5 After-Market EST, actual revenue USD 111.99 M, actual EPS USD -0.1124

LifeMD to Release FY2025 Q2 Earnings on August 5 After-Market EST, Forecast Revenue USD 66.31 M, EPS USD -0.0083

KeyCorp Raises LifeMD's Target Price to $14

LifeMD Announces Dividend Payment

LifeMD Inc CFO Disposed of Common Stock

Stefan Galluppi Sells LifeMD Shares

LifeMD Annual General Meeting Approves Seven Directors and Confirms Accountant

OPTIMI HEALTH CORP

HCW Biologics

GCL Global

Silexion Therapeutics

MetaVia

Vida Global

Micware

BiomX

MicroAlgo

Tradr 2X Long XNDU Daily ETF

LFMD

LifeMD, Inc. (Nasdaq: LFMD) will participate in two investor conferences: the LD Micro Invitational XVI from May 17-19, 2026, and the B. Riley Securities 26th Annual Investor Conference on May 20-21, 2026. Management will present and hold one-on-one meetings at both events. LifeMD is a leading platform for virtual primary care services, offering telemedicine and specialized treatment across over 200 conditions.

StockTitan

B Riley Financial Pref Share RILYL 7.375 Perp 09/04/25 B

B Riley Financial Pref Share RILYN 6.5 09/30/2026

LifeMD Pref Share LFMDP 8.875 Perp 10/15/22

B Riley Financial Pref Share RILYG 7.25 12/21/27

B Riley Financial Pref Share RILYK 5.5 03/31/26

B Riley Financial Pref Share RILYP 6.875 Perp 10/07/24

B Riley Financial Pref Share RILYZ 5.25 08/31/28

B Riley Financial Pref Share RILYT 6.0 01/31/28

LifeMD to Participate in Upcoming Investor Conferences | LFMD Stock News

Wall Street Zen downgraded LifeMD (NASDAQ:LFMD) from a "hold" to a "sell" rating. Despite this, several analysts maintain positive outlooks, with Cantor Fitzgerald and BTIG Research issuing "overweight" and "buy" ratings, respectively. LifeMD's stock opened at $4.78, with a market cap of $227.53 million. The company reported a quarterly EPS of ($0.20), missing estimates, but had revenue of $50.16 million. Institutional investors hold 35.52% of the stock, which has a 52-week range of $2.56 to $15.84. Analysts rate it as a "Moderate Buy" with an average target price of $9.14.

Market Beat

Health Care Select Sector SPDR

VG Health

iShares US Healthcare Providers

SPDR S&P Health

Hims & Hers Health

Mizuho Financial

Invesco

Mizuho Financial Group, Inc.

LifeMD (NASDAQ:LFMD) Cut to Sell at Wall Street Zen

LifeMD, Inc. reported Q1 earnings with a revenue of $50.2 million, slightly above guidance, and reaffirmed full-year targets of $220-$230 million. The company achieved record subscriber growth, adding 42,000 telehealth subscribers, and saw significant momentum in weight management and Women’s Health. Despite a GAAP net loss of $9.6 million, management remains optimistic about future profitability, citing improvements in gross margins and plans to leverage AI for operational efficiency. LifeMD ended Q1 with $34.5 million in cash and no debt, positioning it well for growth despite current challenges.

Tip Ranks

LifeMD Earnings Call: Growth Surges, Profits Deferred

LifeMD reported Q1 2026 results with revenue of $50.2 million, slightly below last year but above guidance. The adjusted EBITDA loss was $4.5 million, consistent with expectations. Gross margin improved to 88%. Active telehealth subscribers increased by 26% to 365,000. The company reaffirmed its 2026 revenue guidance of $220-$230 million and positive adjusted EBITDA. Analysts rate LFMD stock as a Buy with a $10.00 price target, while TipRanks’ AI Analyst rates it Neutral due to mixed financial performance.

LifeMD Posts Q1 Results, Reaffirms 2026 Profitability Outlook

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

nasdaq

Nasdaq

LifeMD (LFMD) Q1 2026 Earnings Transcript

LifeMD shares are trading lower. The company reported its Q2 financial results.

benzinga_article

Earnings Watch

LifeMD | 8-K: FY2026 Q1 Revenue: USD 50.16 M

LifeMD (NASDAQ:LFMD) is set to release its Q1 2026 earnings on May 5, with analysts predicting a loss of $0.14 per share and revenue of $48.69 million. The company previously reported a loss of $0.04 per share for Q1 2025, missing estimates. LifeMD's stock is currently trading at $4.50, with a market cap of $215.63 million. Analysts have mixed ratings, with a consensus target price of $9.14. Hedge funds have increased their stakes in the company, which specializes in telehealth services.

Virtu Finc

LifeMD (LFMD) Projected to Post Quarterly Earnings on Tuesday

LifeMD(LFMD.US)